GSK Has 25 Potential Launches By Decade’s End; Neuroscience A Focus

GlaxoSmithKline could see 25 new drug launches in the time period from 2007 to 2009, including 12 new chemical entities, eight product line extensions and five vaccines, R&D Chairman Moncef Slaoui stated during a pipeline update with investors Dec. 13 in New York City